Chevallard Daniel R. — SEC Form 4 filings
SEC reporting owner CIK 1706176. 7 Form 4 filings on record with FilingPulse; latest filed 2026-03-30.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-02-27 to 2026-03-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 12,886 shares, $164,280 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 3,405 shares, $2,493 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: purchase of 7,500 shares @ $8.57 ($64,275) in LENZ Therapeutics, Inc., filed 2026-03-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | Chief Financial Officer | 5 | 4 legs · 12,886 sh · $164,280 | — | 3 |
| Viracta Therapeutics, Inc. (VIRX) | CFO and COO | 2 | — | 1 leg · 3,405 sh · $2,493 | 3 |
Form 4 filings — Chevallard Daniel R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-30 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 7,500 @ $8.57 | EDGAR |
| 2026-01-06 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 20 @ $22.71 · Purchase (P): 2,178 @ $22.76 | EDGAR |
| 2024-05-15 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 3,188 @ $15.68 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,405 @ $0.73 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1706176 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →